Cytosorbents Corporation

NasdaqCM:CTSO 株式レポート

時価総額：US$22.6m

Cytosorbents 将来の成長

Future 基準チェック /36

Cytosorbentsは、77.3%と11.1%でそれぞれ年率77.3%で利益と収益が成長すると予測される一方、EPSはgrowで78.4%年率。

主要情報

77.3%

収益成長率

78.43%

EPS成長率

Medical Equipment 収益成長17.1%
収益成長率11.1%
将来の株主資本利益率n/a
アナリストカバレッジ

Low

最終更新日21 May 2026

今後の成長に関する最新情報

Recent updates

ナラティブ更新 • Jun 16

CTSO: Nasdaq Extension And Clinical Data Will Support Future Upside Potential

Analysts have reduced their fair value estimate for Cytosorbents from $10.00 to $5.00, citing updated assumptions that now reflect a higher discount rate, more moderate revenue growth expectations, slightly lower profit margin forecasts, and a modestly lower future P/E multiple. What's in the News Nasdaq granted Cytosorbents a 180 day extension, until September 28, 2026, to regain compliance with the minimum US$1.00 bid price requirement for continued listing under Nasdaq Listing Rule 5550(a)(2).
ナラティブ更新 • Jun 02

CTSO: Nasdaq Compliance Extension Will Support Future Turnaround Potential

Analysts have reduced their fair value estimate for Cytosorbents from $5.00 to $2.88 as they recalibrate assumptions for revenue growth, profit margins, the discount rate, and the stock's future P/E multiple. What's in the News On April 1, 2026, Cytosorbents received a 180 day extension from Nasdaq until September 28, 2026 to regain compliance with the minimum US$1.00 bid price requirement for continued listing.
ナラティブ更新 • May 15

CTSO: ICU Utilization And Nasdaq Compliance Extension Will Support Future Upside

Analysts have kept the fair value estimate for Cytosorbents steady at $0.75. Modest tweaks to assumptions for the discount rate, revenue growth, profit margin, and future P/E reflect updated views on risk, earnings power, and likely valuation multiples.
ナラティブ更新 • Apr 27

CTSO: ICU Adoption And Nasdaq Compliance Efforts Will Support Future Upside

Analysts have maintained their $0.75 price target on Cytosorbents. They cite small adjustments in the discount rate, revenue growth assumptions, and future P/E estimates as they refine their models, while keeping their overall valuation view unchanged.
ナラティブ更新 • Apr 11

CTSO: 2025 Revenue Outlook And ICU Adoption Will Support Upside

Analysts have maintained their $0.75 price target for Cytosorbents, citing only modest adjustments to assumptions for discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall view of the stock’s valuation. What's in the News Nasdaq granted CytoSorbents a 180 day extension, until September 28, 2026, to regain compliance with the US$1.00 minimum bid price requirement for continued listing on the exchange, with the stock remaining listed during this period (Delistings notice).
ナラティブ更新 • Mar 28

CTSO: Steady 2025 Outlook And ICU Therapy Progress Will Support Upside

Analysts have held their fair value estimate for Cytosorbents steady, keeping the implied price target unchanged at $0.75. This reflects slightly adjusted views on discount rate, revenue growth and profit margin assumptions, without a clear shift in overall conviction.
ナラティブ更新 • Mar 12

CTSO: Steady 2025 Revenue Guidance Will Support Measured Long Term Upside

Analysts have made a modest adjustment to their Cytosorbents price target, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E. Taken together, these changes leave their fair value estimate broadly unchanged around $0.75.
ナラティブ更新 • Feb 26

CTSO: Flat 2025 Outlook And Cost Discipline Will Support Measured Upside

Analysts have slightly adjusted their price target for Cytosorbents to reflect updated assumptions around revenue growth, profit margin and future P/E, while keeping the fair value broadly in line at $0.75. What's in the News Cytosorbents issued earnings guidance for the fourth quarter of 2025, with revenue expected to be approximately US$9.2 million, the same figure as guidance for the fourth quarter of 2024 (Key Developments).
ナラティブ更新 • Feb 09

CTSO: Cost Cuts And 2026 Cash Flow Break Even Will Support Upside

Analysts have trimmed their price target on Cytosorbents to reflect a slightly lower assumed discount rate, marginally higher projected revenue growth, improved profit margin expectations, and a modestly lower future P/E multiple. This results in a revised valuation that they see as better aligned with updated assumptions.
ナラティブ更新 • Jan 26

CTSO: Cost Cuts And 2026 Cash Flow Break Even Will Shape Outlook

Narrative Update on Cytosorbents Analysts have kept their price target for Cytosorbents steady at US$0.75, citing updated assumptions that reflect slightly lower discount rates, modestly higher projected revenue growth, a stable profit margin outlook, and a small adjustment to expected future P/E levels. What's in the News Cytosorbents issued earnings guidance for the fourth quarter of 2025, with revenue expected to be approximately US$9.2 million, in line with the fourth quarter of 2024 at US$9.2 million (Key Developments).
ナラティブ更新 • Jan 10

CTSO: Cost Reductions And 2026 Cash Flow Break Even Will Support Upside

Analysts have updated their price target on Cytosorbents and maintained fair value at US$0.75. They have also fine tuned underlying assumptions such as the discount rate, revenue growth, profit margin and future P/E to reflect revised views on the company’s risk and earnings profile.
ナラティブ更新 • Dec 26

CTSO: Cost Cuts And Nasdaq Listing Risk Will Shape Balanced Outlook

Analysts modestly raised their price target on Cytosorbents to reflect a slightly lower discount rate and higher expected future earnings multiples, even as they tempered long term revenue growth assumptions. What's in the News Cytosorbents announced a strategic workforce and cost reduction plan, cutting approximately 10% of its staff and realigning production and operating expenses to target operating cash flow break even by the first quarter of 2026 (Key Developments).
ナラティブ更新 • Dec 12

CTSO: Workforce Cuts And FDA Pathway Are Expected To Shape Outlook

Analysts have trimmed their price target on Cytosorbents from approximately 12.84 dollars to 7.96 dollars. This reflects slightly lower long term revenue growth assumptions, a higher perceived risk profile, and only modestly improved profitability expectations.
分析記事 • Nov 13

Market Cool On Cytosorbents Corporation's (NASDAQ:CTSO) Revenues Pushing Shares 31% Lower

To the annoyance of some shareholders, Cytosorbents Corporation ( NASDAQ:CTSO ) shares are down a considerable 31% in...
分析記事 • Nov 08

Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
ナラティブ更新 • Aug 10

FDA And Health Canada Approval Will Spur ICU Solutions

Cytosorbents’ consensus price target has been raised from $5.00 to $7.00, reflecting improved profitability with net profit margin rising to 12.34% and a more attractive future P/E of 74.11x. What's in the News New studies demonstrate early and intensive CytoSorb® therapy significantly improves clinical outcomes for sepsis and septic shock patients, with peer-reviewed data showing increased survival rates when used intensively and early.
分析記事 • Aug 09

Does Cytosorbents (NASDAQ:CTSO) Have A Healthy Balance Sheet?

NasdaqCM:CTSO 1 Year Share Price vs Fair Value Explore Cytosorbents's Fair Values from the Community and select yours...
分析記事 • Jul 02

Further Upside For Cytosorbents Corporation (NASDAQ:CTSO) Shares Could Introduce Price Risks After 54% Bounce

Cytosorbents Corporation ( NASDAQ:CTSO ) shareholders would be excited to see that the share price has had a great...
User avatar
新しいナラティブ • Apr 11

FDA And Health Canada Decisions Will Advance DrugSorb-ATR Launch

Regulatory decisions on DrugSorb-ATR could drive significant revenue growth, especially in the U.S. and Canada, with a large market opportunity.
分析記事 • Jan 17

Further Upside For Cytosorbents Corporation (NASDAQ:CTSO) Shares Could Introduce Price Risks After 28% Bounce

Cytosorbents Corporation ( NASDAQ:CTSO ) shareholders are no doubt pleased to see that the share price has bounced 28...
分析記事 • Oct 01

The Market Lifts Cytosorbents Corporation (NASDAQ:CTSO) Shares 43% But It Can Do More

Despite an already strong run, Cytosorbents Corporation ( NASDAQ:CTSO ) shares have been powering on, with a gain of...
分析記事 • Jul 04

Investors Continue Waiting On Sidelines For Cytosorbents Corporation (NASDAQ:CTSO)

With a price-to-sales (or "P/S") ratio of 1.3x Cytosorbents Corporation ( NASDAQ:CTSO ) may be sending bullish signals...
分析記事 • Mar 16

Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • Jan 06

Take Care Before Jumping Onto Cytosorbents Corporation (NASDAQ:CTSO) Even Though It's 28% Cheaper

Unfortunately for some shareholders, the Cytosorbents Corporation ( NASDAQ:CTSO ) share price has dived 28% in the last...

業績と収益の成長予測

NasdaqCM:CTSO - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/2028525N/AN/A1
12/31/2027472N/AN/A1
12/31/202638-12N/AN/A2
3/31/202637-12-11-10N/A
12/31/202537-8-13-12N/A
9/30/202537-10-10-10N/A
6/30/202536-10-10-10N/A
3/31/202535-16-14-13N/A
12/31/202436-21-15-14N/A
9/30/202430-20-19-18N/A
6/30/202430-26-22-21N/A
3/31/202431-28-24-23N/A
12/31/202331-29-23-22N/A
9/30/202337-23-22-21N/A
6/30/202336-26-24-22N/A
3/31/202335-31-30-23N/A
12/31/202235-33-35-28N/A
9/30/202236-41-36-28N/A
6/30/202238-36-34-26N/A
3/31/202241-29-24-20N/A
12/31/202143-25-18-14N/A
9/30/202144-16-12-10N/A
6/30/202145-10-11-9N/A
3/31/202143-9-7-5N/A
12/31/202041-8-7-6N/A
9/30/202036-11-10-9N/A
6/30/202032-17-12-11N/A
3/31/202028-18-17-16N/A
12/31/201925-19N/A-17N/A
9/30/201924-21N/A-15N/A
6/30/201923-17N/A-13N/A
3/31/201923-19N/A-13N/A
12/31/201823-17N/A-11N/A
9/30/201821-15N/A-9N/A
6/30/201819-14N/A-8N/A
3/31/201817-10N/A-7N/A
12/31/201715-9N/A-6N/A
9/30/201714-11N/A-7N/A
6/30/201712-10N/A-7N/A
3/31/201711-11N/A-7N/A
12/31/201610-12N/A-7N/A
9/30/20168-9N/A-8N/A
6/30/20167-10N/A-8N/A
3/31/20166-5N/A-8N/A
12/31/20155-9N/A-9N/A
9/30/20154-17N/A-9N/A

アナリストによる今後の成長予測

収入対貯蓄率: CTSOは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 3.5% ) よりも高い成長率であると考えられます。

収益対市場: CTSO今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: CTSO今後 3 年以内に収益を上げることが予想されます。

収益対市場: CTSOの収益 ( 11.1% ) US市場 ( 12.6% ) よりも低い成長が予測されています。

高い収益成長: CTSOの収益 ( 11.1% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CTSOの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/07/20 09:15
終値2026/07/17 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Cytosorbents Corporation 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5

アナリスト機関
Sean LeeH.C. Wainwright & Co.
Anthony PetroneJefferies LLC
Danielle AntalffyLeerink Partners LLC